Blue Ocean Strategy of AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug

Introduction

The blue ocean strategy refers to a situation or a market where there is no irrelevant competition, or where there is negligible competition. The blue ocean strategy of AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug is focused on searching for new markets and business avenues which operate with minimal pricing pressures. The blue ocean strategy can be applied across different sectors and industries, and the businesses that exist within them. AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug blue ocean strategy is pivoted on entering new market spaces, or developing them as well as on innovation focused internally or externally that helps reinvent the industry to ensure no irrelevant competition (Kim & Mauborgne, 2014).

Moving away from saturated markets

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug continues to operate in saturated market spaces, and is restricted in growth and expansion. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug’s businesses often face hurdles in the way of development and are also faced with increasingly intense pricing pressures- and are thus said to operate in a red ocean. A red ocean is marked with cut-throat competition and pricing wars that compromise the profits for all players. Pressures in saturated markets along with narrow growth spaces had forced the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to search for new avenues – vertically or horizontally – to be able to enjoy higher market shares, and swim in blue oceans (Kim & Mauborgne, 2014).

Blue ocean strategy and differentiation

New industry boundaries

As companies and organizations move towards blue oceans, they redraw and redesign industry boundaries. This is possible through innovation and creativity. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug also explores new platforms and channels, as well as means of doing business and is thus able to expand existing industry boundaries. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has also been able to show the potential of developing new industries through its innovations – by identifying new spaces and making the competition irrelevant (Agnihotri, 2016).

Differentiation

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has focused on differentiation under the blue ocean strategy. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug’s efforts towards differentiation are focused on creating unique value for the customers in its product and service offerings (Agnihotri, 2016; Blue Ocean Strategy, 2022).

Cost efficiencies and low cost

Under blue oceans, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug also focuses on maintaining affordability for the value additions and differentiated products and services that it offers. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug commonly continuously reevaluates and reassesses its own processes and systems to maintain high-cost efficiencies (Freedman, 2022).

Value innovation – value addition and low-cost maintenance

In doing so, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to explore blue oceans through value additions as well as affordability for consumers. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to successfully identify what consumer’s value and include it in its offerings and value propositions. At the same time, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to provide the value differentiation at affordable costs. In this manner, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug enjoys high levels of value innovation (Kim, 2002; Kim & Mauborgne, 2014).

Understanding red oceans

Under red oceans, where the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug previously operated, all layers had accepted the predefined structures and boundaries of the industry, and had continued to operate as well as compete within these (The Economic Times, 2022).

Cut throat competition

To be able to remain profitable and successful, players, including the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug within red oceans, focused efforts on developing and maintaining competitive advantages over one another, and other players. This advantage was largely cost-based, as in the case of the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug. In this way, wealth was only redistributed at the expense of other players, and the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug failed to create any new wealth in the red oceans (Kim & Mauborgne, 2005).

Understanding blue oceans

Under the blue ocean strategy, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug operates in an industry and market space that is not marked with set boundaries or structures. These blue ocean structures have been recreated by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug at large, as well as by other players. Other players have also contributed to the restructuring of the industry through innovation (Kim & Mauborgne, 2014).

Restructuring industrial boundaries under the blue ocean strategy

Under the blue ocean strategy, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug is not restricted by predefined rules, barriers, and principles. Instead, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to shift its strategic direction and attention from focusing on supply towards working on developing and creating demand (Blue Ocean Strategy, 2022). The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug, in this manner, is focused on the building of value innovation in its offerings, along with ensuring efforts towards building and maintaining differentiation and cost-effectiveness. In this way, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to immaterialize the competition (Kim & Mauborgne, 2017).

Strategic directions for blue oceans

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has four different strategic directions, which it can choose from four continuing to pursue its blue ocean strategy. All of these strategic directions will strengthen the company’s current business position and will supports its strategy of value addition and cost efficiencies, as well as differentiation – allowing it to develop strong and sustainable market positions. These directions are

Raise

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should assess and evaluate the current industry standards and practices.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should identify loopholes, and areas which can be improved, expanded upon, or developed a new within the industry.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should identify different drivers and factors within the industry boundaries.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should identify through research and observation the different factors that could raise above the existing industry standards (Kim, 2002; Kim & Mauborgne, 2017).

Eliminate

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should assess and observe current industry standards.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug should observe players’ practices within the industry, and relate the same with the industry standards.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug can identify the standards which are not needed, which are obsolete, and which may slow down operations and processes.

• These standards can be eliminated in own operations by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug (Kim & Mauborgne, 2014; Freedman, 2022).

Reduce

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug can also assess an observe industry standards for identifying factors that are not needed, or needed partially.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug can work on reducing these standards to enhance operational performance and maximum utilization of resources as well as value addition (The Economic Times, 2022; Kim & Mauborgne, 2014).

Created

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug can also expand current industry boundaries and standards.

• This expansion will be possible by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug through expanding and creating new standards.

• The new standards can be created by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug through observing industry processes and operations, and identifying potential loopholes.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug can introduce new processes and standards to redesign industry boundaries (Agnihotri, 2016; Kim & Mauborgne, 2005).

Blue ocean strategy: organizational competencies

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to successfully implement the blue ocean strategy because of three important organizational elements (Freedman, 2022). These organizational elements have allowed the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to explore blue oceans, experiment successfully with innovation, and add value to its product offerings. These elements include the following:

Mindset

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a progressive mindset that is rooted in this participative and visionary leadership (Bratton, 2020).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a positive and can-do attitude and mindset.

• This mindset has allowed the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to achieve success through high focus and efforts (Wilson, 2018).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has high motivation levels of employees – which enhances the optimal performance of the organization and has allowed it to explore Blue Ocean through creativity (Kim & Mauborgne, 2017; Kim & Mauborgne, 2005; Wilson, 2018).

Tools

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has access to multiple resources that has allowed it to take advantage of the blue ocean strategy (Mebert & Lowe, 2017).

• These resources AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug capabilities are internal as well as external for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has also invested resources and trainings for developing internal capabilities and capacities for ensuring upgraded skills and increased value addition (Buchanan & Huczynski, 2019; Chernev, 2018).

Culture

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a learning culture, and encourages all employees to ask questions and carry out healthy discussions (Anthony, 2021; Schein, 2010).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a culture that is focused on research and development, which in turn leads to new innovations and solutions for existing demands and challenges (Wunder, 2019).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has an inclusive and diverse culture, which leads to increased synergies that allow the development and implementation of blue ocean strategies easily (Wilson, 2018).

Using the blue ocean strategy effectively: steps for successful implementation

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has developed the blue ocean strategy following systematic and organized processes and steps (Kim & Mauborgne, 2017). The steps that the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug undertook for developing the blue ocean strategy include:

Step1

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug conducted thorough market and industry research to identify the right place to work towards developing a core team (Kim & Mauborgne, 2014; Freedman, 2022). This core team was responsible for driving AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug forward strategically towards new value additions and differentiations (Blue Ocean Strategy, 2022; Kim & Mauborgne, 2017 b).

Step2

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug continued to conduct deep market analysis as well as studied and assessed the competition closely. This was needed by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to identify potential opportunities, and demand gaps in the existing industry as well as potential structural changes in the existing industrial boundaries (Blue Ocean Strategy, 2022).

Step3

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug’s assessment of the macro environment, and the market spaces allowed it to also identify the challenges and issues hidden in the current industry structure and design (Machado, 2019; Kim & Mauborgne, 2017 b). These issues and problems have restricted the industry size, and led to restrictive growth for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug was also blue to identify new non-customers in this assessment- which could be turned into future consumers (Blue Ocean Strategy, 2022).

Step4

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug worked to redesign and reconstruct the industry boundaries and structures in a systematic manner. This was done through identifying new opportunities, as well as through exploring new innovations and valuations in existing offerings (Blue Ocean Strategy, 2022).

Step5

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug finally elected the right blue ocean move, i.e. conducted various pilot testing’s and market testing for its new offerings before finalizing and launching them in the market to attract new consumers, and explore new markets (Blue Ocean Strategy, 2022).

Tackling challenges on the way to Blue Ocean

Restructuring and reorganizing the boundaries and structures of the industries is not that simple (Anthony, 2021; Kim & Mauborgne, 2017 b). Managers and practitioners of the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug seek to renew the value of their offerings within the organization – mostly using new technologies and advances networks to not only create value propositions, but also transform existing ones (Kim & Mauborgne, 2005; Kim, 2002). However, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to overcome resistance towards change and innovation within the organization, as well as in the external environments, because of:

Organizational culture

The culture within the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug supports exploration and innovation. This culture is important for supporting the development and implementation of new ideas that boost the value propositions of the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug (Chernev, 2018; Bratton, 2020; Martinez, Beaulieu, & Gibbons, 2015).

Business design

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug also continually practices business design (Freedman, 2022). The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug ensures that it’s leading from the font. This means that the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug ensures that its teams are empowered, and confident in tackling ambiguous and difficult challenges and issues. This allows the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to identify new opportunities and innovate (Wunder, 2019).

Strong and visionary leadership

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a forward-thinking, progressive, charismatic leadership. This leadership ensures that the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug continually engages in disruptive processes and innovations – which in turn allow the company to explore and implement the blue ocean strategy. The leadership is supportive of, and facilitates the change processes within the company (Machado, 2019).

Communication

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug ensures that all communication within the organization is transparent and quick (Chernev, 2018; Buchanan & Huczynski, 2019). The leadership and management levels have frequent meetings within the company along managerial levels (Wilson, 2018; Wunder, 2019). This allows employees to feel on board of the happenings, and be part of a change from the beginning – understanding its need and facilitating its implementation. This is critical for ensuring successful innovation and adoption of the blue ocean strategy (Anthony, 2021; Chernev, 2018; Kim, 2002).

Value innovation in blue ocean strategy

Value innovation within the blue ocean strategy focuses on value as well as innovation (Blue Ocean Strategy, 2022; Kim & Mauborgne, 2017). This means that the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug seeks to innovate and create value at the same time as a means of differentiation within the marketplace to be able to implement the blue ocean strategy (Kim & Mauborgne, 2014). The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug does not only engage in value creation – which focuses on scaling the existing value only instead of creating a new one (Blue Ocean Strategy, 2022; Agnihotri, 2016; Kim & Mauborgne, 2014).

Technology innovation

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug engages in value innovation through technology innovation. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug ensures that it uses advanced and progressive technology to address various consumer demands and problems as well as needs in innovative ways and manners (Kim & Mauborgne, 2005). However, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug ensures that it focuses on value innovation rather than technology innovation in its value propositions so that new value through technology is created for consumers (Kim, 2002; Wilson, 2018).

Low cost

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug also ensures affordability with value innovation. The value innovation allows the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to operate at low costs, and maintain cost efficiencies (Chernev, 2018). As a result, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug maintains low costs and high value for consumers – allowing it to tap into new consumer groups as well. As a result, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug is able to enjoy a high growth rate as well as increased sales and profits (Kim & Mauborgne, 2014).

The strategies and strategic directions for designing and implementing the blue ocean strategy have been overseen through some guiding and fundamental principles by the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug. These include”

Formulation principles

Redesigning the industry

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug sought to reconstruct, redesign and rebuild the market boundaries and standards.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug was bold enough to redefine the industry space and the market space in which it operated (Mebert & Lowe, 2017).

Long term focus

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug focused on long-term success and sustainability, instead of short-term gains and numbers.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug was visionary, and aw beyond the existent customer demand and needs (Freedman, 2022).

Demand creation

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug creates demand for the new value-added offerings it manufactured and proposed in the blue oceans (Kim, 2002).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug tapped into new customer groups and target audiences (Kim & Mauborgne, Red Ocean Traps (Harvard Business Review Classics), 2017 b).

Execution principles

Overcoming organizational challenges

Organizational culture

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a result organizational culture (Martinez, Beaulieu, & Gibbons, 2015; Schein, 2010).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug invests in research and development.

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug is quick to adapt to change and has a disciplined change management team to oversee change processes (Chernev, 2018; Kim & Mauborgne, 2014).

Environmental assessment

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug continually assesses its internal and external environments and creates contingency plans (Chernev, 2018; Machado, 2019).

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug engages in pre-strategic planning to help strengthen its strategic focus and direction (Wilson, 2018; Kim & Mauborgne, 2017 b).

Leadership

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a visionary leadership (Bratton, 2020).

• The leadership at the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has a participative approach which encourages employee motivation and their organizational commitment.

• The leadership ensures optimal organizational performance at the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug (Freedman, 2022; Kim & Mauborgne, 2005).

Developing execution strategy

• The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has developed a sequential strategic direction for execution.

• The execution of the blue ocean strategy is based on market research (Anthony, 2021).

• The execution of the blue ocean strategy has been carefully planned to ensure that it’s timely.

• The execution involves all parts and members of the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug (The Economic Times, 2022; Kim, 2002).

Blue ocean strategic Tools

The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to use multiple operational and strategic tools.

Shift in organizational mindset

These tools kits have been important for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug in helping it develop the right mindset needed for aligning processes and systems towards the blue ocean strategic direction (Kim & Mauborgne, 2017 b). The tools have been a powerful source for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug in facilitating it towards aligning its resources, and identifying potential blue oceans (Kim, 2002). The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been diligent in ensuring that its teams and organizational members are familiar with the blue can strategies and tools so that the shift in their mindset is facilitated and strengthened (Wunder, 2019).

Cultural driver

Moreover, the tools also ensure increased alignment of the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug’s culture with the strategy. This, in turn, has allowed the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to realize the increased number of opportunities, and embed creativity in its internal processes and systems (Kim, 2002; Buchanan & Huczynski, 2019).

These tools include, for example:

• Value innovation

• Six path framework

• Strategy canvas

• Four action framework

• Tipping point leadership

• ERRC Grid

• Pioneer settler migrator map

• Buyer utility map

• 3 tiers of non-customers

• Fair processes

• Visualizing strategy (The Economic Times, 2022)

Conclusion

With the use of the blue ocean strategy, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to redesign the industrial boundaries and standards using multiple techniques and tools that have been identified and discussed briefly in this paper.

The blue ocean strategy has been an important strategic element for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to explore new markets and tap into new customer groups through using the blue ocean strategy. This has been possible for the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug through continuous investment in research and development as well as through its organizational cultural, which is focused on innovation and creativity. The AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has been able to make use of innovative processes and progressive technology to create value innovation. At the same time, the AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug has moved out of red oceans and no longer competes over pricing strategies. This has also allowed AstraZeneca Prilosec and Nexium Marketing Challenges in the Launch of a Second-Generation Drug to build a cost advantage, and maintain affordability in its offerings for customers.

References

Agnihotri, A. (2016). Extending boundaries of blue ocean strategy. Journal of Strategic Marketing, 24 (6), 519-528.

Anthony, H. (2021). Understanding strategic management. New York: Oxford University Press.

Blue Ocean Strategy. (2022). WHAT IS BLUE OCEAN STRATEGY? Retrieved 2022, from Blue Ocean Strategy: https://www.blueoceanstrategy.com/what-is-blue-ocean-strategy/

Bratton, J. (2020). Organizational leadership. Newcastle upon Tyne: Sage.

Buchanan, D., & Huczynski, A. (2019). Organizational behaviour. London: Pearson UK.

Chernev, A. (2018). Strategic marketing management. Berlin/Heidelberg: Cerebellum Press.

Freedman, M. (2022). Blue Ocean Strategy: Creating Your Own Market . Retrieved 2022, from https://www.businessnewsdaily.com/5647-blue-ocean-strategy.html

Kim, W. (2002). Blue ocean strategy: from theory to practice. California management review, 47 (3), 105-121.

Kim, W., & Mauborgne, R. (2005). Value innovation: a leap into the blue ocean. Journal of business strategy .

Kim, W., & Mauborgne, R. (2014). Blue ocean strategy, expanded edition: How to create uncontested market space and make the competition irrelevant. Boston, Massachusetts: Harvard business review Press.

Kim, W., & Mauborgne, R. (2017 b). Red Ocean Traps (Harvard Business Review Classics). Boston, Massachusetts: Harvard Business Review Press.

Kim, W., & Mauborgne, R. (2017). Blue ocean leadership (Harvard business review classics). Boston, Massachusetts, United States: Harvard Business Review Press.

Machado, C. (2019). Organizational Behaviour and Human Resource Management. Berlin: Springer.

Martinez, E., Beaulieu, N., & Gibbons, R. (2015). Organizational culture and performance. American economic review, 105 (5), 331-35.

Mebert, A., & Lowe, S. (2017). Blue Ocean Strategy. Literary Criticism.

Schein, E. (2010). Organizational culture and leadership. Hoboken, New Jersey: John Wiley & Sons.

The Economic Times. (2022). What is 'Blue Ocean Strategy' . Retrieved 2022, from https://economictimes.indiatimes.com/definition/blue-ocean-strategy

Wilson, F. (2018). Organizational behaviour and work: a critical introduction. New York: Oxford university press.

Wunder, T. (2019). Rethinking strategic management: Sustainable strategizing for positive impact. Berlin: Springer Nature.